Network Pharmacology and Molecular Docking Study of Zhishi-Baizhu Herb Pair in the Treatment of Gastric Cancer

Table 3

Results of KEGG enrichment analysis (top 20).

ID	Description	value	adjusted	Count
hsa05215	Prostate cancer	4.71E-20	7.21E-18	21
hsa01522	Endocrine resistance	5.93E-20	7.21E-18	21
hsa05212	Pancreatic cancer	4.76E-18	3.85E-16	18
hsa05163	Human cytomegalovirus infection	1.99E-16	1.16E-14	25
hsa04151	PI3K-Akt signalling pathway	2.39E-16	1.16E-14	30
hsa05167	Kaposi’s sarcoma-associated herpesvirus infection	7.92E-16	3.21E-14	23
hsa05223	Non-small cell lung cancer	1.15E-15	4.00E-14	16
hsa01524	Platinum drug resistance	1.46E-15	4.44E-14	16
hsa05161	Hepatitis B	2.96E-15	7.99E-14	21
hsa05222	Small cell lung cancer	3.78E-15	8.53E-14	17
hsa05219	Bladder cancer	3.86E-15	8.53E-14	13
hsa04933	AGE-RAGE signaling pathway in diabetic complications	1.63E-14	3.30E-13	17
hsa05210	Colorectal cancer	2.32E-14	4.26E-13	16
hsa05169	Epstein-Barr virus infection	2.46E-14	4.26E-13	22
hsa05162	Measles	2.63E-14	4.26E-13	19
hsa01521	EGFR tyrosine kinase inhibitor resistance	1.16E-13	1.75E-12	15
hsa04210	Apoptosis	2.38E-13	3.41E-12	18
hsa05166	Human T-cell leukaemia virus 1 infection	1.29E-12	1.74E-11	21
hsa04657	IL-17 signaling pathway	1.68E-12	2.07E-11	15
hsa05145	Toxoplasmosis	1.70E-12	2.07E-11	16